JP4950656B2 - 核酸検出 - Google Patents
核酸検出 Download PDFInfo
- Publication number
- JP4950656B2 JP4950656B2 JP2006504214A JP2006504214A JP4950656B2 JP 4950656 B2 JP4950656 B2 JP 4950656B2 JP 2006504214 A JP2006504214 A JP 2006504214A JP 2006504214 A JP2006504214 A JP 2006504214A JP 4950656 B2 JP4950656 B2 JP 4950656B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sars
- primer
- dna
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims description 104
- 108020004707 nucleic acids Proteins 0.000 title claims description 94
- 102000039446 nucleic acids Human genes 0.000 title claims description 94
- 238000001514 detection method Methods 0.000 title claims description 72
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 124
- 230000003321 amplification Effects 0.000 claims description 121
- 241000315672 SARS coronavirus Species 0.000 claims description 119
- 238000000034 method Methods 0.000 claims description 116
- 238000003753 real-time PCR Methods 0.000 claims description 93
- 239000000523 sample Substances 0.000 claims description 70
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 67
- 108020004414 DNA Proteins 0.000 claims description 57
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 54
- 239000002299 complementary DNA Substances 0.000 claims description 42
- 108020004635 Complementary DNA Proteins 0.000 claims description 33
- 238000010804 cDNA synthesis Methods 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 230000000295 complement effect Effects 0.000 claims description 20
- 238000002405 diagnostic procedure Methods 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 16
- 238000002955 isolation Methods 0.000 claims description 14
- 102000053602 DNA Human genes 0.000 claims description 13
- 241000711573 Coronaviridae Species 0.000 claims description 12
- 230000007613 environmental effect Effects 0.000 claims description 11
- 230000010076 replication Effects 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 3
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 2
- 239000013615 primer Substances 0.000 description 89
- 238000003752 polymerase chain reaction Methods 0.000 description 73
- 108090000623 proteins and genes Proteins 0.000 description 46
- 229920002477 rna polymer Polymers 0.000 description 28
- 230000035945 sensitivity Effects 0.000 description 20
- 241000700605 Viruses Species 0.000 description 15
- 239000012472 biological sample Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 108020000999 Viral RNA Proteins 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 238000011002 quantification Methods 0.000 description 8
- 230000004544 DNA amplification Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000003155 DNA primer Substances 0.000 description 6
- 238000007857 nested PCR Methods 0.000 description 6
- 239000002987 primer (paints) Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 241000319420 SARS coronavirus HKU-39849 Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 230000002934 lysing effect Effects 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- -1 SARS coronavirus Chemical class 0.000 description 2
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 2
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 239000010865 sewage Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101001024647 Severe acute respiratory syndrome coronavirus Nucleoprotein Proteins 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0310181A GB2401175A (en) | 2003-05-02 | 2003-05-02 | Detection of SARS virus by PCR |
| GB0310181.3 | 2003-05-02 | ||
| PCT/CN2004/000434 WO2004097021A1 (en) | 2003-05-02 | 2004-04-30 | Nucleic acid detection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011235645A Division JP2012080884A (ja) | 2003-05-02 | 2011-10-27 | 核酸検出 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006524996A JP2006524996A (ja) | 2006-11-09 |
| JP2006524996A5 JP2006524996A5 (https=) | 2007-06-14 |
| JP4950656B2 true JP4950656B2 (ja) | 2012-06-13 |
Family
ID=33155801
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504214A Expired - Fee Related JP4950656B2 (ja) | 2003-05-02 | 2004-04-30 | 核酸検出 |
| JP2011235645A Withdrawn JP2012080884A (ja) | 2003-05-02 | 2011-10-27 | 核酸検出 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011235645A Withdrawn JP2012080884A (ja) | 2003-05-02 | 2011-10-27 | 核酸検出 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080090224A1 (https=) |
| EP (2) | EP2597162A1 (https=) |
| JP (2) | JP4950656B2 (https=) |
| KR (4) | KR101097560B1 (https=) |
| CN (1) | CN1798842A (https=) |
| GB (1) | GB2401175A (https=) |
| TW (3) | TWI362419B (https=) |
| WO (1) | WO2004097021A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3836160A1 (en) * | 2019-12-13 | 2021-06-16 | Autonomous Medical Devices Inc. | An automated, cloud-based, point-of-care (poc) pathogen and antibody array detection method |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101603096A (zh) * | 2009-05-04 | 2009-12-16 | 北京海康基因芯片开发有限公司 | 一种检测传染病病原体的方法及试剂盒 |
| CN102424863B (zh) * | 2012-01-06 | 2013-06-12 | 海康生物科技（北京）有限公司 | 一种增强型荧光定量pcr方法 |
| US12416053B2 (en) * | 2020-02-04 | 2025-09-16 | Indian Institute Of Technology Delhi | Primer sets, biomarkers, kit and applications thereof |
| US11649511B2 (en) * | 2020-02-06 | 2023-05-16 | Daan Gene Co., Ltd. | Multiplex PCR method for the detection of SARS-CoV-2 |
| IT202000006754A1 (it) | 2020-03-31 | 2021-10-01 | Diasorin S P A | Saggi per la rivelazione di SARS-CoV-2 |
| US11149320B1 (en) | 2020-03-31 | 2021-10-19 | Diasorin S.P.A. | Assays for the detection of SARS-CoV-2 |
| CN111455102A (zh) * | 2020-04-09 | 2020-07-28 | 上海符贝基因科技有限公司 | 用于新冠病毒SARS-CoV-2基因组靶向测序的捕获探针制备方法 |
| AU2021202504A1 (en) * | 2020-04-29 | 2021-11-18 | Teleflex Medical Incorporated | System for identifying severe acute respiratory syndrome corona virus 2 (sars-cov-2) ribonucleic acid (rna) |
| CN111635960B (zh) * | 2020-05-06 | 2023-06-27 | 温州医科大学附属眼视光医院 | 用于稳态速效检测新型冠状病毒的保护序列、引物、探针、组合物、试剂盒及应用和方法 |
| WO2021247398A1 (en) * | 2020-05-30 | 2021-12-09 | Pangolin Llc | Systems and methods to detect pathogens |
| JPWO2022030629A1 (https=) * | 2020-08-07 | 2022-02-10 | ||
| US11361847B1 (en) | 2021-02-06 | 2022-06-14 | Timothy A. Hodge | System and method for rapidly reporting testing results |
| KR102625074B1 (ko) * | 2021-04-20 | 2024-01-16 | 재단법인 아산사회복지재단 | 마이크로입자 기반 핵산 검출용 키트 및 핵산 증폭산물 검출 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1493602A (en) * | 2000-10-05 | 2002-04-15 | Hong Kong Dna Chips Ltd | A kit for detecting non-pathogenic or pathogenic influenza a subtype h5 virus |
| US6617137B2 (en) * | 2001-10-15 | 2003-09-09 | Molecular Staging Inc. | Method of amplifying whole genomes without subjecting the genome to denaturing conditions |
| AU2002346660A1 (en) * | 2001-11-30 | 2003-06-17 | University Of Rochester | Multiplex real-time quantitative pcr |
| WO2004085455A1 (en) * | 2003-03-24 | 2004-10-07 | The University Of Hong Kong | A diagnostic assay for the human virus causing severe acute respiratory syndrome (sars) |
| CN102021147B (zh) * | 2003-03-24 | 2016-08-03 | 港大科桥有限公司 | 引起严重急性呼吸道综合征(sars)的新型人病毒及其应用 |
| ES2529736T3 (es) * | 2003-04-10 | 2015-02-25 | Novartis Vaccines And Diagnostics, Inc. | Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS |
| EP1616038A2 (en) * | 2003-04-21 | 2006-01-18 | Genome Institute of Singapore | Reagents and methods for detecting severe acute respiratory syndrome coronavirus |
| CN1442488A (zh) * | 2003-05-16 | 2003-09-17 | 上海晶泰生物技术有限公司 | 传染性非典型肺炎（sars）病毒复合荧光定量pcr检测 |
-
2003
- 2003-05-02 GB GB0310181A patent/GB2401175A/en not_active Withdrawn
-
2004
- 2004-04-30 EP EP12199212.7A patent/EP2597162A1/en not_active Withdrawn
- 2004-04-30 JP JP2006504214A patent/JP4950656B2/ja not_active Expired - Fee Related
- 2004-04-30 KR KR1020107016726A patent/KR101097560B1/ko not_active Expired - Fee Related
- 2004-04-30 TW TW100121077A patent/TWI362419B/zh not_active IP Right Cessation
- 2004-04-30 TW TW093112238A patent/TWI377255B/zh not_active IP Right Cessation
- 2004-04-30 KR KR1020057020758A patent/KR101158934B1/ko not_active Expired - Fee Related
- 2004-04-30 WO PCT/CN2004/000434 patent/WO2004097021A1/en not_active Ceased
- 2004-04-30 EP EP04730463A patent/EP1620556A4/en not_active Withdrawn
- 2004-04-30 TW TW101123035A patent/TW201245452A/zh unknown
- 2004-04-30 KR KR1020127020392A patent/KR20120094155A/ko not_active Ceased
- 2004-04-30 KR KR1020117004874A patent/KR20110027854A/ko not_active Abandoned
- 2004-04-30 US US10/555,467 patent/US20080090224A1/en not_active Abandoned
- 2004-04-30 CN CNA200480014935XA patent/CN1798842A/zh active Pending
-
2011
- 2011-10-27 JP JP2011235645A patent/JP2012080884A/ja not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3836160A1 (en) * | 2019-12-13 | 2021-06-16 | Autonomous Medical Devices Inc. | An automated, cloud-based, point-of-care (poc) pathogen and antibody array detection method |
| EP3836159A1 (en) * | 2019-12-13 | 2021-06-16 | Autonomous Medical Devices Inc. | An automated, cloud-based, point-of-care (poc) pathogen and antibody array detection system |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110027854A (ko) | 2011-03-16 |
| KR20050118738A (ko) | 2005-12-19 |
| CN1798842A (zh) | 2006-07-05 |
| WO2004097021A1 (en) | 2004-11-11 |
| KR101097560B1 (ko) | 2011-12-22 |
| TWI362419B (en) | 2012-04-21 |
| EP1620556A4 (en) | 2010-09-15 |
| TW201139687A (en) | 2011-11-16 |
| JP2012080884A (ja) | 2012-04-26 |
| TW201245452A (en) | 2012-11-16 |
| EP1620556A1 (en) | 2006-02-01 |
| TWI377255B (en) | 2012-11-21 |
| EP2597162A1 (en) | 2013-05-29 |
| US20080090224A1 (en) | 2008-04-17 |
| KR20100090730A (ko) | 2010-08-16 |
| TW200502400A (en) | 2005-01-16 |
| GB2401175A (en) | 2004-11-03 |
| KR20120094155A (ko) | 2012-08-23 |
| JP2006524996A (ja) | 2006-11-09 |
| KR101158934B1 (ko) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sharma et al. | COVID-19 diagnosis: current and future techniques | |
| JP2012080884A (ja) | 核酸検出 | |
| CN111593145B (zh) | 一种CRISPR/Cas12一步核酸检测方法及新型冠状病毒检测试剂盒 | |
| Batten et al. | A real time RT-PCR assay for the specific detection of Peste des petits ruminants virus | |
| Liang et al. | Rapid detection and tracking of Omicron variant of SARS-CoV-2 using CRISPR-Cas12a-based assay | |
| CN111004870B (zh) | 新型冠状病毒n基因核酸检测试剂盒 | |
| CN113930547B (zh) | 猪流行性腹泻病毒n基因的rt-raa荧光法检测引物对、试剂盒及检测方法 | |
| CN112739833B (zh) | 利用巢式RPA技术检测SARS-CoV-2的引物对、探针、试剂盒及其应用 | |
| Chen et al. | Rapid detection of SARS-CoV-2 using duplex reverse transcription-multienzyme isothermal rapid amplification in a point-of-care testing | |
| CN111286559B (zh) | 检测非洲猪瘟病毒的引物、探针及试剂盒 | |
| Cojocaru et al. | Microchip RT-PCR detection of nasopharyngeal SARS-CoV-2 samples | |
| KR102267326B1 (ko) | 코로나 바이러스 진단방법 및 진단용 키트 | |
| Song et al. | Identification of human metapneumovirus genotypes A and B from clinical specimens by reverse transcription loop-mediated isothermal amplification | |
| Alhamlan et al. | Development and validation of an in-house, low-cost SARS-CoV-2 detection assay | |
| Mahony et al. | Development of a novel bead-based multiplex PCR assay for combined subtyping and oseltamivir resistance genotyping (H275Y) of seasonal and pandemic H1N1 influenza A viruses | |
| CN120249562A (zh) | RT-RPA-CRISPR/Cas12a一步法快速检测乙型流感病毒的技术及其应用 | |
| CN108753768A (zh) | 用于检测肠道病毒的核酸及其应用 | |
| Liu et al. | Detection and identification of SARS-CoV-2 and influenza a based on microfluidic technology | |
| Nikpey et al. | Nanomolecular magnetic probe for colorimetric RT-LAMP of Viral RNA | |
| Paryan et al. | Design and development of a multiplex real-time PCR assay for detection of HIV-1 and HCV using molecular beacons | |
| CN115989323A (zh) | 检测SARS-CoV-2感染的方法 | |
| RU2858313C1 (ru) | Набор олигонуклеотидных праймеров и флуоресцентно-меченого зонда для выявления РНК вируса Хендра (Henipavirus hendraense) методом ОТ-ПЦР в режиме реального времени | |
| CN113512609A (zh) | 新型冠状病毒实时荧光核酸恒温扩增检测试剂盒及其专用引物和探针 | |
| KR101402397B1 (ko) | Ａ형 인플루엔자 ｈ１ｎ１ 바이러스 검출용 키트 | |
| Alhamlan et al. | Development and Validation of Two In-house, Low-Cost SARS-CoV-2 Detection Assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070416 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070416 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100302 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100602 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100609 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100702 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100709 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100802 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100902 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111027 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20111212 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120221 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120309 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150316 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |